2001糖皮质素诱导的骨质疏松症的预防和治疗指南(英文)-美国风湿病学会.docVIP

Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis 2001 Update American College Of Rheumatology Ad Hoc Committee On Glucocorticoid-Induced Osteoporosis Members of the American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis are as follows. Lenore Buckley, MD, MPH: Medical College of Virginia, Richmond; Maria Greenwald, MD: Palm Springs, California; Marc Hochberg, MD, MPH: University of Maryland School of Medicine, Baltimore; Nancy Lane, MD: University of California San Francisco School of Medicine; Stephen Lindsey, MD: Ochsner Clinic, Baton Rouge, Louisiana; Stephen Paget, MD: Cornell University School of Medicine, New York, New York; Ken Saag, MD, MSc: University of Alabama School of Medicine, Birmingham; Lee Simon, MD: Harvard University School of Medicine, Boston, Massachusetts. The American College of Rheumatology is an independent professional, medical, and scientific society which does not guarantee, warrant, or endorse any commercial product or service. Address correspondence and reprint requests to American College of Rheumatology, 1800 Century Place, Suite 250, Atlanta, GA 30345. Submitted for publication March 19, 1999; accepted in revised form April 11, 2001. Funded by:Merck Co., Aventis Pharmaceuticals, Wyeth Ayerst, Bristol-Myers Squibb, Procter Gamble, La Jolla Pharmaceuticals, Amgen, Novartis Pharmaceuticals, AstraZeneca Pharmaceuticals, Forest Pharmaceuticals,Abgenix, Vertex, G. D. Searle Co., Pharmacia Glucocorticoid therapy is associated with a number of significant side effects, of which bone loss resulting in glucocorticoid-induced osteoporosis and an increase in fracture risk is the most serious (1-4). However, studies show that many patients treated with glucocorticoids do not receive treatment to prevent bone loss (5-7). This suggests that physician awareness of bone loss and the increase in fracture risk caused by glucocorticoid treatment is low, and that there is inad